Elaheh Emadi et al., 2024: Narrative review with a history section that dates the 1876 synthesis, Ehrlich's 1891 antimalarial use, and states that clinical use was stopped because of the unavoidable blue discoloration of urine, sclera and skin.
In 1891, its ability to target the malaria organisms was identified by Paul Ehrlich; that was the beginning of its therapeutic application, but its use was stopped due to its unavoidable unfavorable effects (reversible bluish coloration of urine, sclera, and skin)
Elaheh Emadi et al., 2024: Narrative review with a history section that dates the 1876 synthesis, Ehrlich's 1891 antimalarial use, and states that clinical use was stopped because of the unavoidable blue discoloration of urine, sclera and skin. C1 historical account inside a narrative review (Iran J Basic Med Sci 2024;27(7):780-792; PMID 38800024; doi 10.22038/ijbms.2024.71871.15617). No primary data, no N. The stated reason for disuse is the staining side effect, not patent status. No statement in the text on off-patent status or funding difficulty. text_file=A_04.txt FLAG: no pharmacopoeia-deletion record was found. Searches of USP/BP status did not produce a document removing methylene blue from a national pharmacopoeia; current FDA labeling still reads 'methylene blue injection, USP', so no deletion claim is made here. Also filed as MTL-058 (claims C1, C4). Study type: review.
